ES3013130T3 - High dose and low volume botulinum toxin treatment of facial wrinkles - Google Patents

High dose and low volume botulinum toxin treatment of facial wrinkles Download PDF

Info

Publication number
ES3013130T3
ES3013130T3 ES21728601T ES21728601T ES3013130T3 ES 3013130 T3 ES3013130 T3 ES 3013130T3 ES 21728601 T ES21728601 T ES 21728601T ES 21728601 T ES21728601 T ES 21728601T ES 3013130 T3 ES3013130 T3 ES 3013130T3
Authority
ES
Spain
Prior art keywords
botulinum toxin
treatment
dose
glabellar
injected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21728601T
Other languages
English (en)
Spanish (es)
Inventor
Susanna Roll
Meik Sladek
Thorin Geister
Irena Pulte
Petra Weissenberger
Gudrun Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71016459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3013130(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Application granted granted Critical
Publication of ES3013130T3 publication Critical patent/ES3013130T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES21728601T 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles Active ES3013130T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20178574 2020-06-05
PCT/EP2021/064986 WO2021245223A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Publications (1)

Publication Number Publication Date
ES3013130T3 true ES3013130T3 (en) 2025-04-11

Family

ID=71016459

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21728601T Active ES3013130T3 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Country Status (13)

Country Link
US (2) US12599550B2 (enExample)
EP (2) EP4161562B1 (enExample)
JP (2) JP2023529095A (enExample)
KR (1) KR20230020961A (enExample)
CN (1) CN115666629A (enExample)
AU (1) AU2021286196A1 (enExample)
BR (1) BR112022023413A2 (enExample)
CA (1) CA3177835A1 (enExample)
ES (1) ES3013130T3 (enExample)
IL (1) IL298399A (enExample)
MX (1) MX2022014564A (enExample)
TW (1) TW202214211A (enExample)
WO (1) WO2021245223A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
TWI852454B (zh) * 2022-04-01 2024-08-11 大陸商重慶譽顏製藥有限公司 一種肉毒毒素蛋白組合物、製備方法及其應用
KR20250113431A (ko) * 2022-11-28 2025-07-25 메르츠 파마 게엠베하 운트 코. 카가아 목을 재생하기 위한 고 농도 보툴리눔 독소 치료
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP1786459B1 (en) 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
LT2761065T (lt) * 2011-09-29 2018-01-10 Cellsnap, Llc Kompozicijos ir būdai toksigeniškumo testavimui
US11976110B2 (en) 2013-06-28 2024-05-07 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2020121540A (ru) 2017-12-04 2022-01-10 Реванс Терапьютикс, Инк. Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Also Published As

Publication number Publication date
EP4161562A1 (en) 2023-04-12
EP4467202A2 (en) 2024-11-27
KR20230020961A (ko) 2023-02-13
US20260144733A1 (en) 2026-05-28
JP2023529095A (ja) 2023-07-07
MX2022014564A (es) 2022-12-15
EP4161562B1 (en) 2024-11-20
WO2021245223A1 (en) 2021-12-09
CN115666629A (zh) 2023-01-31
EP4467202A3 (en) 2025-02-19
TW202214211A (zh) 2022-04-16
CA3177835A1 (en) 2021-12-09
AU2021286196A1 (en) 2022-12-01
JP2026077675A (ja) 2026-05-13
US12599550B2 (en) 2026-04-14
IL298399A (en) 2023-01-01
US20230329996A1 (en) 2023-10-19
BR112022023413A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
US10973890B2 (en) Non-protein clostridial toxin compositions
ES2907652T3 (es) Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen un efecto terapéutico o cosmético de larga duración
EP4161562B1 (en) High dose and low volume botulinum toxin treatment of facial wrinkles
US20230158129A1 (en) Clostridial toxin - hyaluronic acid compositions
JP2022130574A (ja) ボツリヌス毒素を含む組成物
KR101959234B1 (ko) 혈관 과민반응과 관련된 피부질환을 치료하기 위한 방법 및 조성물
US20170157020A1 (en) Method of treatment of wrinkles using topical chemodenervating agents
KR20230086752A (ko) 경부 근긴장이상증의 치료 방법
RU2835617C1 (ru) Лечение морщин на лице высокой дозой и малым объемом ботулинического токсина
KR20250113429A (ko) 하안부와 목을 재생하기 위한 광경근에의 보툴리눔 독소 주사
US20240000905A1 (en) Polymeric nanoparticle compositions for encapsulation and sustained release of neuromodulators
KR20250113350A (ko) 비-복합체 보툴리눔 독소 조성물의 빠른 효력 발현 효과 및 이와 관련된 방법
HK40085901A (en) High dose and low volume botulinum toxin treatment of facial wrinkles
US20240207303A1 (en) mNA-based Delivery of Botulinum Toxin
KR20240032688A (ko) 내성 발현이 감소된 보툴리눔 독소 제제 및 이와 관련된 방법
WO2024115413A1 (en) High concentration botulinum toxin treatment for neck rejuvenation